UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

/x/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2001

Commission File Number 0-9314

ACCESS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	83-0221517
(State of Incorporation)	(I.R.S. Employer I.D. No.)

2600 Stemmons Frwy, Suite 176, Dallas, TX 75207

(Address of principal executive offices)

Telephone Number (214) 905-5100

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirement for the past 90 days.

Yes X No
--- ---

The number of shares outstanding of each of the issuer's classes of common stock, as of August 14, 2001 was 12,856,569 shares of common stock, $0.01 par value per share.

Total No. of Pages 12

PART I -- FINANCIAL INFORMATION

ITEM 1 FINANCIAL STATEMENTS

The response to this Item is submitted as a separate section of this report.

ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Access Pharmaceuticals, Inc. is a Delaware corporation in the development stage. We are an emerging pharmaceutical company focused on developing both novel low development risk product candidates and technologies with longer-term major product opportunities. Together with our subsidiaries, we have proprietary patents or rights to five technology platforms: synthetic polymers, bioerodible hydrogels, Residerm TM, carbohydrate targeting technology and agents for the prevention and treatment of viral disease, including HIV. In addition, our partner, GlaxoSmithKline (formerly Block Drug Company), is marketing in the United States a product, Aphthasol R, a drug jointly developed, the first U.S. Food and Drug Administration (or FDA) approved product for the treatment of canker sores. We are developing new formulations

and delivery forms to evaluate this product in additional clinical indications. We have licensed certain rights for the use of amlexanox in additional indications from GlaxoSmithKline for numerous markets excluding the U. S. and the worldwide rights for mucositis.

Except for the historical information contained herein, the following discussions and certain statements in this Form 10-Q are forward-looking statements that involve risks and uncertainties. In addition to the risks and uncertainties set forth in this Form 10-Q, other factors could cause actual results to differ materially, including but not limited to our research and development focus, uncertainties associated with research and development activities, clinical trials, uncertainty associated with preclinical and clinical testing, the timing of regulatory approvals, future cash flow, timing and receipt of licensing revenues, collaborations, dependence on others, and other risks detailed in our reports filed under the Securities Exchange Act of 1934, as amended, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2000.

Since our inception, we have devoted our resources primarily to fund our research and development programs. We have been unprofitable since inception and to date have received limited revenues from the sale of products. We cannot assure you that we will be able to generate sufficient product revenues to attain profitability on a sustained basis or at all. We expect to incur losses for the next several years as we continue to invest in product research and development, preclinical studies, clinical trials and regulatory compliance. As of June 30, 2001, our accumulated deficit was $34,569,000, of which $8,894,000 was the result of the write-off of excess purchase price of mergers.

LIQUIDITY AND CAPITAL RESOURCES

Working capital as of June 30, 2001 was $22,025,000 representing a decrease in working capital of $2,372,000 as compared to the working capital as of December 31, 2000 of $24,397,000. The

decrease in working capital was due to the loss from operations for the first six months of 2001.

Since inception, our expenses have significantly exceeded revenues, resulting in an accumulated deficit as of June 30, 2001 of $34,569,000. We have funded our operations primarily through private sales of common stock and convertible notes. Contract research payments from corporate alliances and mergers have also provided funding for operations.

We have incurred negative cash flows from operations since inception, and have expended, and expect to continue to expend in the future, substantial funds to complete our planned product development efforts. We expect that our existing capital resources will be adequate to fund our current level of operations through the year 2003.

We will require substantial funds to conduct research and development programs, preclinical studies and clinical trials of potential products. Our future capital requirements and adequacy of available funds will depend on many factors, including:

* the successful commercialization of amlexanox;
* the ability to establish and maintain collaborative arrangements with corporate partners for the research, development and commercialization of products;
* continued scientific progress in our research and development programs;
* the magnitude, scope and results of preclinical testing and clinical trials;
* the costs involved in filing, prosecuting and enforcing patent claims;
* competing technological developments;
* the cost of manufacturing and scale-up;
* the ability to establish and maintain effective commercialization arrangements and activities; and
* successful regulatory filings.

SECOND QUARTER 2001 COMPARED TO SECOND QUARTER 2000

Revenue in the second quarter of 2001 was $10,000, as compared to no revenue in the same period of 2000. Revenue in the second quarter of 2001 is

recognized over the period of the performance obligation of several licensing agreements, including various amlexanox projects.

Total research spending for the second quarter of 2001 was $1,032,000, as compared to $1,069,000 for the same period in 2000, a decrease of $37,000. The decrease in expenses was the result of:

* lower clinical development costs ($221,000) for amlexanox product development projects for OraDisc TM. Costs for this project were incurred in the second quarter 2000 and minimal costs were incurred in the second quarter 2001 due to the completion of OraDisc TM trials in 2000 and early 2001; and

* other net decreases ($34,000).

The decrease in expenses was partially offset by:

* higher clinical development costs ($131,000) for amlexanox cream and gel projects due to the start of clinical trials in 2001; and

* higher scientific salary cost ($87,000) due to additional employees on staff.

We expect research spending to increase in future quarters and remain higher than in prior quarters as we intend to hire additional scientific and clinical staff, commence additional clinical trials and accelerate preclinical development activities as we continue to develop our product candidates.

Total general and administrative expenses were $463,000 for the second quarter of 2001, a decrease of $24,000 as compared to the same period in 2000. The decrease in spending was due primarily to lower compensation expenses ($99,000).

These general and administrative expenses decreases were partially offset by:

* higher patent costs ($21,000);

* higher shareholder expenses ($21,000); and

* other net increases ($33,000).

Depreciation and amortization was $99,000 for the second quarter of 2001 as compared to $112,000 for the same period in 2000 reflecting a decrease of $13,000. The decrease in amortization is due to lower depreciation reflecting that some major assets have been fully depreciated.

Total operating expenses in the second quarter of 2001 were $1,594,000 as compared to total operating expenses of $1,668,000 for the same period in 2000.

Loss from operations in the second quarter of 2001 was $1,584,000 as compared to a loss of $1,668,000 for the same period in 2000.

Interest and miscellaneous income was $350,000 for the second quarter of 2001 as compared to $223,000 for the same period in 2000, an increase $127,000. The increase in interest income was due to higher cash balances in 2001 resulting from our private placements of common stock and convertible note offering in 2000.

Interest expense was $283,000 for the second quarter of 2001 as compared to $1,000 for the same period in 2000, an increase of $282,000. The increase in interest expense was due to interest accrued in 2001 on the $13.5 million convertible notes that were issued in 2000 and amortization of debt issuance costs.

Net loss in the second quarter of 2001 was $1,517,000, or a $0.12 basic and diluted loss per common share, compared with a loss of $1,446,000, or a $0.13 basic and diluted loss per common share for the same period in 2000.

SIX MONTHS ENDED JUNE 30, 2001 COMPARED TO SIX MONTHS ENDED JUNE 30, 2000

Revenue in the first six months of 2001 was $221,000, as compared to no revenue in the same period of 2000. Revenue in the first six months of 2001 is

recognized over the period of the performance obligation of several licensing agreements, including various amlexanox projects and ResiDerm TM.

Total research spending for the first six months of 2001 was $2,035,000, as compared to $1,672,000 for the same period in 2000, an increase of $363,000. The increase in expenses was the result of:

* higher clinical development costs ($262,000) for amlexanox product development projects for OraDisc TM, cream and gel projects. The first Phase III study evaluating OraDisc TM was completed and a second Phase III study is scheduled to commence in 2001. During the first six months of 2001 we also commenced Phase I amlexanox gel and cream studies; and

* higher scientific salary costs ($146,000) due to additional employees;

The increase in expenses was partially offset by:

* lower moving expenses for scientific personal ($42,000); and

* other net decreases ($3,000).

We expect research spending to increase in future quarters and remain higher than in prior quarters as we intend to hire additional scientific and clinical staff, commence additional clinical trials and accelerate preclinical development activities as we continue to develop our product candidates.

Total general and administrative expenses were $899,000 for the first six months of 2001, a decrease of $17,000 as compared to the same period in 2000. The decrease in spending was due primarily to the following:

* lower compensation expenses ($81,000);

* lower listing fees in 2001 due to our initial listing on the American Stock Exchange in 2000 ($32,000); and

* other net decreases ($2,000).

These general and administrative expense decreases were partially offset by:

* higher shareholder expenses ($56,000); and

* higher patent costs ($42,000).

Depreciation and amortization was $201,000 for the first six months of 2001 as compared to $223,000 for the same period in 2000 reflecting a decrease of $22,000. The decrease in amortization was due to lower depreciation reflecting that some major assets have been fully depreciated.

Total operating expenses in the first six months of 2001 were $3,135,000 as compared to total

operating expenses of $2,811,000 for the same period in 2000.

Loss from operations in the first six months of 2001 was $2,914,000 as compared to a loss of $2,811,000 for the same period in 2000.

Interest and miscellaneous income was $792,000 for the first six months of 2001 as compared to $288,000 for the same period in 2000, an increase of $504,000. The increase in interest income was due to higher cash balances in 2001 resulting from our private placements of common stock and convertible note offering in 2000.

Interest expense was $566,000 for the first six months of 2001 as compared to $3,000 for the same period in 2000, an increase of $563,000. The increase is interest expense is due to interest accrued on the $13.5 million convertible notes issued in 2000 and amortization of debt issuance costs.

Net loss in the first six months of 2001 was $2,688,000, or a $0.21 basic and diluted loss per common share, compared with a loss of $2,526,000, or a $0.26 basic and diluted loss per common share for the same period in 2000.

PART II -- OTHER INFORMATION

ITEM 1 LEGAL PROCEEDINGS

The Company is not a party to any material legal proceedings.

ITEM 2 CHANGES IN SECURITIES

None.

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The annual meeting of stockholders was held on May 21, 2001 in New York, NY. At that meeting the following matters were submitted to a vote of the stockholders of record. The proposals were approved by the stockholders, as follows:

* Three directors were reelected for three year terms with the following votes:
  Herbert H. McDade, Jr., 7,348,123 - For; and 42,828 - Withheld Authority
  Kerry P. Gray; 7,348,121 - For; and 42,830 - Withheld Authority
  J. Michael Flinn; 6,948,117 - For; and 442,834 - Withheld Authority

* The terms of office as a director of Access of each of Stephen B. Howell, Max Link, John J. Meakam, Jr. and Preston Tsao continued after the meeting.

* A proposal to amend our 1995 stock option plan, as amended, to adjust the number of options to be granted annually to non-employee directors from 5,000 to 10,000 shares of common stock was approved with 6,887,955 - For; 494,316 - Against; and 8,680 - Abstain.

* A proposal to approve the 2001 Access Pharmaceuticals, Inc. restricted stock plan was approved with 7,305,848 - For; 78,421 - Against; and 6,682 - Abstain.

* A proposal to ratify the appointment of Grant Thornton LLP as independent certified public accountants for the Company for the fiscal year ending December 31, 2001 was approved with 6,953,025 - For; 434,438 - Against; and 3,487 - Abstain.

ITEM 5 OTHER INFORMATION

None

ITEM 6 EXHIBITS AND REPORTS ON FORM 8-K

Exhibits: 10.19 Supplemental Lease Agreement between Pollock Realty Corporation and us dated February 9, 2001

Reports on Form 8-K:

None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

ACCESS PHARMACEUTICALS, INC.

Date: August 14, 2001 By:/s/ Kerry P. Gray

Kerry P. Gray

President and Chief Executive Officer

Date: August 14, 2001 By:/s/ Stephen B. Thompson

Stephen B. Thompson
Vice President and Chief Financial Officer

Access Pharmaceuticals, Inc. and Subsidiaries
(a development stage company)

Condensed Consolidated Balance Sheets

<TABLE>
<CAPTION>

	June 30, 2001	December 31, 2000
ASSETS	(unaudited)	
<S>	<C>	<C>
Current assets		
Cash and cash equivalents	$ 5,615,000	$ 8,415,000
Short term investments, at cost	18,174,000	17,394,000
Accounts receivable	1,000	251,000
Accrued interest receivable	68,000	196,000
Prepaid expenses and other current assets	68,000	133,000
Total current assets	23,926,000	26,389,000
Property and equipment, net	128,000	116,000
Debt issuance costs, net	770,000	861,000
Licenses, net	831,000	887,000
Goodwill, net	1,992,000	2,115,000
Other assets	159,000	158,000
Total assets	$ 27,806,000	$ 30,526,000
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued expenses	$ 615,000	$ 1,158,000
Accrued interest payable	756,000	283,000
Deferred revenues	530,000	551,000
Total current liabilities	1,901,000	1,992,000
Convertible notes	13,530,000	13,530,000
Total liabilities	15,431,000	15,522,000
Commitments and contingencies	-	-
Stockholders' equity		
Preferred stock - $.01 par value; authorized 2,000,000 shares; none issued or outstanding	-	-
Common stock - $.01 par value; authorized 50,000,000 shares; issued, 12,856,569 at June 30, 2001 and 12,844,669 at December 31,2000	133,000	132,000
Additional paid-in capital	47,860,000	47,802,000
Notes receivable from stockholders	(1,045,000)	(1,045,000)
Treasury stock, at cost - 819 shares	(4,000)	(4,000)
Deficit accumulated during the development stage	(34,569,000)	(31,881,000)
Total stockholders' equity	12,375,000	15,004,000

Total liabilities and stockholders' equity	$ 27,806,000	$ 30,526,000

</TABLE>

The accompanying notes are an integral part of these statements.

Access Pharmaceuticals, Inc. and Subsidiaries
(a development stage company)

Condensed Consolidated Statements of Operations
(unaudited)

<TABLE>
<CAPTION>

	Three months ended June 30,		Six months ended June 30,		February 24, 1988 (inception) to
	2001	2000	2001	2000	June 30, 2001
<S>	<C>	<C>	<C>	<C>	<C>
Revenues					
Research and development	$ -	$ -	$ -	$ -	$ 2,711,000
Option income	-	-	-	-	2,164,000
Licensing revenues	10,000	-	221,000	-	653,000
Total revenues	10,000	-	221,000	-	5,528,000
Expenses					
Research and development	1,032,000	1,069,000	2,035,000	1,672,000	18,015,000
General and administrative	463,000	487,000	899,000	916,000	12,560,000
Depreciation and amortization	99,000	112,000	201,000	223,000	2,177,000
Write-off of excess purchase price	-	-	-	-	8,894,000
Total expenses	1,594,000	1,668,000	3,135,000	2,811,000	41,646,000
Loss from operations	(1,584,000)	(1,668,000)	(2,914,000)	(2,811,000)	(36,118,000)
Other income (expense)					
Interest and miscellaneous income	350,000	223,000	792,000	288,000	2,649,000
Interest and debt expense	(283,000)	(1,000)	(566,000)	(3,000)	(1,100,000)
	67,000	222,000	226,000	285,000	1,549,000
Net loss	$(1,517,000)	$(1,446,000)	$(2,688,000)	$(2,526,000)	$ (34,569,000)
Basic and diluted loss per common share	$(0.12)	$(0.13)	$(0.21)	$(0.26)	
Weighted average basic and diluted common shares outstanding	12,853,923	11,479,207	12,851,149	9,547,679	

</TABLE>

The accompanying notes are an integral part of these statements.

Access Pharmaceuticals, Inc. and Subsidiaries
(a development stage company)

Condensed Consolidated Statements of Cash Flows
(unaudited)

<TABLE>
<CAPTION>

	Six months ended June 30,	February 24, 1988

			(inception) to
	2001	2000	June 30, 2001
<S>	<C>	<C>	<C>
Cash flows form operating activities:			
Net loss	$(2,688,000)	$(2,526,000)	$(34,569,000)
Adjustments to reconcile net loss to cash used in operating activities:			
Write-off of excess purchase price	-	-	8,894,000
Warrants issued in payment of consulting expenses	41,000	-	970,000
Research expenses related to common stock granted	-	-	100,000
Depreciation and amortization	201,000	223,000	2,177,000
Amortization of debt costs	91,000	-	145,000
Deferred revenue	(21,000)	428,000	420,000
Change in operating assets and liabilities:			
Accounts receivable	250,000	48,000	(2,000)
Accrued interest receivable	128,000	(100,000)	(68,000)
Prepaid expenses and other current assets	65,000	46,000	(69,000)
Licenses	-	(100,000)	(525,000)
Other assets	(1,000)	-	(7,000)
Accounts payable and accrued expenses	(543,000)	88,000	(147,000)
Accrued interest payable	473,000	-	756,000
Net cash used in operating activities	(2,004,000)	(1,893,000)	(21,925,000)
Cash flows from investing activities:			
Capital expenditures	(34,000)	(63,000)	(1,279,000)
Sales of capital equipment	-	-	15,000
Purchases of short term investments and certificates of deposit	(780,000)	(12,519,000)	(18,174,000)
Purchase of businesses, net of cash acquired	-	-	(226,000)
Other investing activities	-	-	(150,000)
Net cash used in investing activities	(814,000)	(12,582,000)	(19,814,000)
Cash flows from financing activities:			
Proceeds from notes payable	-	-	721,000
Payments of principal on obligations under capital leases	-	(26,000)	(750,000)
Purchase of treasury stock	-	(750,000)	(754,000)
Cash acquired in merger with Chemex	-	-	1,587,000
Notes receivable from shareholders	-	-	(1,045,000)
Proceeds from convertible note, net	-	-	12,615,000
Proceeds from stock issuances, net	18,000	15,381,000	34,980,000
Net cash provided by financing activities	18,000	14,605,000	47,354,000
Net increase (decrease) in cash and cash equivalents	(2,800,000)	130,000	5,615,000
Cash and cash equivalents at beginning of period	8,415,000	869,000	-
Cash and cash equivalents at end of period	$ 5,615,000	$ 999,000	$ 5,615,000

</TABLE>

The accompanying notes are an integral part of these statements.

Notes to Condensed Consolidated Financial Statements
Six Months Ended June 30, 2001 and 2000
(unaudited)

(1) Interim Financial Statements

The consolidated balance sheet as of June 30, 2001 and the consolidated statements of operations and cash flows for the three and six months ended June 30, 2001 and 2000 were prepared by management without audit. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made.

Certain amounts have been reclassified to conform with current period classification.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2000. The results of operations for the period ended June 30, 2001 are not necessarily indicative of the operating results which may be expected for a full year. The consolidated balance sheet as of December 31, 2000 contains financial information taken from the audited financial statements as of that date.

SUPPLEMENTAL LEASE AGREEMENT

This Supplemental Lease Agreement is made and entered into this 9th day of February, 2001 by and between:

Landlord
POLLOCK REALTY CORPORATION
c/o TIG Real Estate Services, Inc.
P. O. Box 802047
Dallas, Texas 75380-2047

and

Tenant
Access Pharmaceuticals, Inc.
2600 Stemmons Freeway, Suite 164-176
Dallas, Texas 75207-2107

This Supplemental Lease Agreement shall modify the original Lease Agreement between Pollock Realty Corporation (Landlord), and Access Pharmaceuticals, Inc. (Tenant) dated on or about July 25, 1996 in which certain real estate and premises therein described and situated in the County of Dallas, City of Dallas and the State of Texas were demised and leased by Landlord and Tenant.

It is the sole intent of this Supplemental Lease Agreement to modify the Original Lease Agreement by the following provisions:

1. Landlord and Tenant hereby agree that effective March 15, 2001 The Premises shall include Suites 164-176 and the rentable square footage contained in the Premises is deemed to be 11,684 net rentable square feet and the rentable square footage of the Building is deemed to be 39,733 net rentable square feet and Tenant's proportionate share of the Building is 29.41%

2. Beginning on the March 15, 2001 the monthly base rental as referenced in Paragraph 2.A. of the original Lease Agreement shall be as follows:

Dates	Base Rent
3/15/01-3/31/01	$5,312.77
4/1/01-3/31/02	$9,687.98
4/1/02-3/31/03	$9,785.35
4/1/03-3/31/04	$9,882.72
4/1/04-3/31/05	$9,980.08
4/1/05-3/31/06	$10,077.45

3. Landlord, at its sole cost and expense, will replace the 3-ton HVAC unit serving the conference room in Suite 176.

4. Landlord will provide $40,000.00 for the construction of the improvements to the Premises. All improvements shall be performed according to Landlord's specifications and shall include all costs for architecture/space planning.

5. It is agreed and understood that if Tenant is not in default of any of the terms, covenants and conditions hereof and Tenant has not assigned this Lease or sublet the Premises (or part thereof), Tenant shall have the option to terminate this Supplemental Lease Agreement according to the dates and terms set forth below. Such termination is conditioned upon Tenant's providing prior notice to Landlord through registered or certified mail and upon the payment schedule as follows to Landlord:

* Effective 4/1/03= $60,000.00 plus all unamortized tenant improvements and all unamortized commissions ($44,772.00)

* Effective 4/1/04= $50,000.00 plus all unamortized tenant improvements and all unamortized commissions ($29,850.00)

* Effective 4/1/05= $40,000.00 plus all unamortized tenant improvements and all unamortized commissions ($14,925.00)

The above payment will serve as a termination fee at this time of notice to Landlord. Notice of Tenant's intention to terminate this Lease Agreement and payment of termination fee must be received by Landlord in writing not less than one hundred eighty (180) days prior to the to the effective date of termination. Said date of termination would be effective as if thedate had been the original termination date under this Lease Agreement. Accordingly, Tenant shall be liable and responsible for its obligation and liabilities under the Lease Agreement, which include but are not limited to, excess tax assessments. In the event Tenant fails to deliver such notice of termination and payment of termination fee within the time period set forth above, this Lease shall remain in full force and effect.

6. If during the term of this Lease, any of the immediately adjacent Premises as described or indicated in Exhibit A attached hereto (hereinafter referred to as the "Adjacent Premises"), shall become available for lease to third parties, and provided that Tenant is not in default hereunder and has not assigned this Lease or sublet the Premises (or part hereof), Tenant shall have the first right and option to lease the Adjacent Premises subject to the rights of other Tenants in the Building. When the Adjacent Premises becomes available, Landlord shall first offer in writing any such Adjacent Premises to Tenant upon the terms and conditions as would be offered by Landlord to third parties. If within ten (10) days after Landlord delivers Tenant such written offer, Landlord does not receive notice in writing that Tenant elects to lease the Adjacent Premises and within twenty (20) days thereafter Tenant does not execute an expansion agreement acceptable to Landlord then Tenant's right to lease the Adjacent Premises shall be waived and tenant shall have no further rights pursuant to this Paragraph 5.

7. Landlord and Tenant represent each to the other that it has full right and authority to enter into this Supplemental Lease Agreement.

Except as expressly provided herein all of the other terms and conditions of the Lease shall remain in effect and unchanged.

SIGNED BY LANDLORD, this 9th day of February, 2001.

POLLOCK REALTY CORPORATION

BY: /S/ RICHARD R. POLLOCK

PRINTED NAME: RICHARD R. POLLOCK
TITLE: COUNSEL

ADDRESS: C/O TIG REAL ESTATE SERVICES, INC.
P. O. BOX 802047
DALLAS, TEXAS 75380-2047
PHONE: 972-661-0232
FAX: 972-661-0235

SIGNED BY TENANT, this 9th day of February, 2001.

ACCESS PHARMACEUTICALS, INC.

BY: /S/ KERRY P. GRAY

PRINTED NAME: KERRY P. GRAY
TITLE: PRESIDENT AND CEO

ADDRESS: 2600 STEMMONS FREEWAY
SUITE 176
DALLAS, TEXAS 75207
PHONE: 214-905-5100
FAX: 214-905-5101

EXHIBIT A
ADJACENT PREMISES

2600 Stemmons Freeway
Site Plan